You just read:

Regeneron Presents Positive Interim Data from Phase 2 Proof-of-Concept Study of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

News provided by

Regeneron Pharmaceuticals, Inc.

31 May, 2016, 09:00 ET